NUV-868 Alone and in Combination With PARP Inhibitors in Patients With Advanced Solid Tumors
Clinicaltrials.gov identifier:
NCT05252390
Treatment
Treatment study for people with advanced solid tumors, including triple-negative breast, ovarian, pancreatic and prostate cancer
Study Contact Information:
Clinical Trials at Nuvation Bio by phone: 332-208-6102
or by email: [email protected]
NUV-868 Alone and in Combination With PARP Inhibitors in Patients With Advanced Solid Tumors
About the Study
This study will test how safe and effective the experimental drug NUV-868 is by itself and in combination with a in people with advanced . The first part of the study will include people with any solid tumor type, and the second part will include people with triple-negative breast, ovarian, pancreatic or cancers only.
Type of Study
This is an study, meaning participants and their doctors will know which drug(s) are being given. The study will be run in different phases and will have different groups. The dose and combination of treatments participants receive will depend on their cancer type and when they enroll in the study.
What the Study Involves
This study will have different phases and groups.
All participants will receive the study drug NUV-868. The dose will vary based on when people enroll in the study. Some participants will receive a second drug in combination with NUV-868. The combination will depend on their cancer type and when they enrolled in the study.
- Participants with will receive either NUV-868 alone or in combination with the oral olaparib.
- Participants with pancreatic cancer will receive either NUV-868 alone or in combination of NUV-868 and the oral olaparib.
- Participants with ovarian cancer will receive either NUV-868 alone or in combination of NUV-868 and the oral olaparib.
- Participants with castration-resistant cancer will one of the following: NUV-868 alone, NUV-868 in combination with or NUV-868 in combination with .
- Participants with other than those listed above, may enroll in Phase 1 of the study only. These participants will receive NUV-868 alone.
Participants will continue treatment unless their cancer gets worse, they develop serious side-effects, they decide to stop participating or the study is stopped.
The duration of the trial is expected to be 12 months.
California
City: Los Angeles RECRUITING
Facility: Ellison Institute of Technology
Contact Info:
[email protected]
310-272-7640
[email protected]
310-272-7640
Colorado
City: Aurora RECRUITING
Facility: Rocky Mountain Cancer Centers, LLP
Contact Info:
[email protected]
303-385-2067
City: Denver RECRUITING
Facility: Rocky Mountain, Cancer Centers, LLP
Contact Info:
[email protected]
303-385-2067
City: Lone Tree RECRUITING
Facility: Rocky Mountain Cancer Centers, LLP
Contact Info:
[email protected]
303-385-2067
Maryland
City: Baltimore RECRUITING
Facility: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Contact Info:
[email protected]
410-955-1057
Michigan
City: Detroit RECRUITING
Facility: Karmanos Cancer Institute
Contact Info:
[email protected]
313-576-8912
New York
City: New York RECRUITING
Facility: Laura & Isaac Perlmutter Cancer Center - NYU Langone Health
Contact Info:
[email protected]
347-266-2630
City: New York RECRUITING
Facility: Memorial Sloan Kettering Cancer Center
Contact Info:
[email protected]
646-422-4600
Pennsylvania
City: Philadelphia RECRUITING
Facility: Abramson Cancer Center of the U of Penn.
Contact Info:
[email protected]
267-414-6179
Tennessee
City: Nashville RECRUITING
Facility: Sarah Cannon Research Institute - Tennessee Oncology
Contact Info:
[email protected]
Texas
City: Dallas RECRUITING
Facility: Mary Crowley Cancer Research
Contact Info:
[email protected]
972-566-3000
City: Dallas RECRUITING
Facility: Texas Oncology - Baylor Charles A. Sammons Cancer Center
Contact Info:
[email protected]
214-370-1942
City: Fort Worth RECRUITING
Facility: Texas Oncology - Fort Worth Cancer Center
Contact Info:
[email protected]
817-413-1760
City: Houston RECRUITING
Facility: Center for Oncology and Blood Disorders
Contact Info:
[email protected]
713-301-8964
[email protected]
832-540-1951
Virginia
City: Fairfax RECRUITING
Facility: NEXT Virginia
Contact Info:
[email protected]
210-580-9500
Other Countries
Country: Australia
State: New South Wales
City: North Ryde RECRUITING
Facility: Macquarie University Hospital
Contact Info:
[email protected]
61 2 9812 2956
[email protected]
61 2 9812 2959
Country: Australia
State: New South Wales
City: Waratah RECRUITING
Facility: Calvary Mater Hospital Newcastle
Contact Info:
[email protected]
61 2 4014 3563
[email protected]
61 2 4014 3291
Country: Australia
State: Victoria
City: Malvern RECRUITING
Facility: Cabrini Hospital Malvern
Contact Info:
[email protected]
1300 300 977
[email protected]
61 3 9508 3596
Country: Australia
State: Victoria
City: Melbourne RECRUITING
Facility: Peter Maccallum Cancer Centre
Contact Info:
[email protected]
61 3 8559 5000
[email protected]
61 3 8559 5000
Country: Australia
State: Western Australia
City: Nedlands RECRUITING
Facility: Linear Clinical Research
Contact Info:
[email protected]
+61(0)419395975
[email protected]
+61(08) 6382 5115
Phase 1 is open to people with advanced whose cancer has progressed during or after treatment with approved therapies or for which there is no standard effective treatment available.
Phase 2 is open to people diagnosed with the following advanced or cancers:
- triple-negative breast cancer
- participants with a or mutation must have received treatment.
- platinum-resistant or platinum-refractive ovarian cancer
- participants with a or mutation or a mutation associated with DNA-damage repair must have received treatment.
- pancreatic cancer
- participants with a or mutation must have received treatment.
- castration-resistant cancer
- participants with a or mutation or a mutation associated with DNA-damage repair must have received treatment.
- People with cancer spread to their brain or central nervous system.
- People who are pregnant or breastfeeding.